An advisory group, composed of representatives of UK pharmaceutical and biotechnology companies, is urging the government to help the industry preserve access to the EU's market and researchers after Brexit, reported Bloomberg.
The UK EU Life Sciences Steering Group, headed by GlaxoSmithKline CEO Andrew Witty and AstraZeneca CEO Pascal Soriot, called on the government to be "flexible" during EU exit talks.
According to the Association of the British Pharmaceutical Industry, the group met with UK ministers last week and highlighted the importance of predictable funding for scientific research, the right to trade and move capital across borders, regulatory cooperation and the ability to tap international talent.
The next meeting between the steering group and the UK government will take place in November.
To read more NewsPoints articles, click here.